News
05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage ... “All the hope I had in the safety of this approach has been supported by the data from this trial thus far,” said ...
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback